Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Am Soc Clin Oncol Educ Book ; 42: 1-10, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1808489

ABSTRACT

Evidence-based education is crucial for meeting the evolving needs of learners in the oncology workforce, given the growing demand for well-trained providers and the rapidly changing complexities of cancer care. With the onset of the severe acute respiratory syndrome coronavirus 2 pandemic, innovative means of delivering educational content in a virtual setting have become a necessary reality. Knowledge of learning science can be translated into concrete, pragmatic methods for using evidence-based education in a virtual world and affords important opportunities for innovation and inclusion across a broad network of educators and learners. We offer key insights and tools to promote attention to and agility with teaching in virtual settings to meet the needs of contemporary educators and learners.


Subject(s)
COVID-19 , COVID-19/epidemiology , Humans , Pandemics , SARS-CoV-2
2.
Blood Adv ; 5(22): 4662-4665, 2021 11 23.
Article in English | MEDLINE | ID: covidwho-1443790

ABSTRACT

We report a case of vaccine-induced immune thrombotic thrombocytopenia (VITT) in a young man diagnosed 13 days after Ad26.COV2.S COVID-19 (Johnson & Johnson/Janssen) vaccination. He presented to us with 5 days of progressive left leg pain, thrombocytopenia, hypofibrinogenemia, and markedly elevated d-dimers, but without radiographically demonstrable thrombosis. Despite negative imaging, we initiated treatment of presumptive VITT given the striking clinical picture that included the timing of his recent adenovirus-based COVID-19 vaccine, leg symptoms, marked thrombocytopenia, and consumptive coagulopathy. He received intravenous immune globulin, prednisone, and argatroban and was discharged 7 days later much improved. His positive platelet factor 4 enzyme-linked immunosorbent assay antibody test returned after treatment was initiated. To our knowledge, this is the first reported case of VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis. Our patient highlights the importance of knowing vaccine status and initiating treatment as soon as possible in the right clinical setting, even in the absence of radiographic evidence of thrombus. Early VITT recognition and treatment provide an opportunity to prevent serious thrombotic complications.


Subject(s)
COVID-19 Vaccines/adverse effects , COVID-19 , Thrombocytopenia , Thrombosis , Ad26COVS1 , COVID-19/prevention & control , Humans , Male , Thrombocytopenia/chemically induced , Thrombosis/chemically induced , Thrombosis/drug therapy , Vaccination/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL